Navigation Links
Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
Date:8/26/2014

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. As this disease progresses, scarring in the lungs increases and patients gradually lose the ability to breathe, leading ultimately to death in two to five years after diagnosis.

WISP1 (also known as CCN4) is an autocrine and paracrine extracellular stimulus involved in several detrimental profibrotic processes. Preclinical studies have shown that WISP1: 1) is induced in human lung cells by key profibrotic growth factors, such as TGF-B, 2) is upregulated at the alveolar epithelial surface in IPF; 3) causes protein induced hyperplasia and proliferation of alveolar epithelial cells accompanied by increased expression of matrix metalloproteinases and fibroblast-like phenotypic changes; 4) protein stimulates fibroblasts to deposit extracellular matrix in vitro: and 5) when depleted with neutralizing murine antibodies attenuates bleomycin-induced pulmonary fibrosis in vivo.

Sorrento was awarded a Small Business Innovation Research (SBIR) Phase 1 grant from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), which will support the development of the fully human anti-WISP1 antibodies discovered by Sorrento. The principal investigator on the SBIR grant is Sorrento's Senior Director of R&D Dr. Gunnar F. Kaufmann. He will work closely with Dr. Melanie Konigshoff at Comprehensive Pneumology Center (CPC) in Munich Germany'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Sorrento Therapeutics to Present at Two Healthcare Conferences
11. Sorrento Therapeutics Completes IgDraSol Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  The University of Maryland,s A. James Clark School ... the new A. James Clark Hall at the University ... transformative new engineering and biomedical technologies to accelerate advancements ... a.m. on November 21 at the site of the ... to the Jeong H. Kim Engineering Building, the event ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... , Nov. 21, 2014  PTC Therapeutics, Inc. (NASDAQ: ... 2014 Legend of Technology Award for Vision, Innovation, and Leadership ... Chief Executive Officer. This award recognizes an individual who has ... New Jersey for several decades. ... Award," stated Stuart Peltz , Ph.D., CEO of PTC ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
... Aug. 13 Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly cash dividend of 11 ... 15, 2010 to shareholders of record at the close ... Laboratories develops, acquires, manufactures and markets electronic instruments and ...
... (Nasdaq: www.mylan.com . Forward-Looking Statements ... that constitute "forward-looking statements." These statements are made pursuant ... Litigation Reform Act of 1995. Because such statements inherently ... materially from those expressed or implied by such forward-looking ...
Cached Medicine Technology:
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... November 24, 2014 The typical American ... the wrong ingredients. Consistently consuming a diet high in ... stores of excess fat that typically accumulate around the ... rearing its ugly head in the form of love ... dieters make the decision to rid themselves of the ...
(Date:11/24/2014)... November 24, 2014 Dr. Michael Kettel ... Center, recently appeared on NBC to discuss egg freezing as ... has been trending in the news recently, with new company ... for women. , “[The companies] see it as ... on a career hot path.” Says Dr. Kettel. , Up ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a ... great promotion for many products, especially the beautiful colored ... best choice with amazing discounts, up to 90% off. ... It is easy to buy colored wedding dresses in ... is also famous for delicate craftsmanship, elegant style and ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
Breaking Medicine News(10 mins):Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3
... primary biliary cirrhosis may lead to new treatments, researchers ... have found genetic variations that appear to increase the ... that can destroy the liver. , Primary biliary cirrhosis ... in the liver. It is a condition that mostly ...
... find similar results , WEDNESDAY, June 10 (HealthDay News) ... drugs after radiation therapy do better when the drug treatment ... six-month regimen, a European study has found. , The results ... in May, said Dr. Eric M. Horwitz, acting chairman of ...
... Geodon have been linked to certain health risks, experts note, ... and Drug Administration advisory panel on Wednesday voted ... approved to treat schizophrenia and bipolar disorder in children aged ... a decision on Geodon, a third antipsychotic in the ...
... Children,s National ... ... Imaging of critically ill children can now be done with minimal disruption and risk at ... of Potomac, Maryland, partnered with Children,s National to make imaging safer in the pediatric ...
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier ... said today that J. Melville Engle, the Company,s Chief Executive ... appointment brings the total number of directors to six. , ... management experience in the healthcare industry, joined the Company as ...
... Trust for America,s Health (TFAH) today applauded the U.S. Senate ... strong prevention and public health components in the Affordable Health ... , "Our nation will never be able to contain ... keeping Americans healthier and preventing disease," said Jeff Levi, Ph.D., ...
Cached Medicine News:Health News:Genetic Links to Rare Liver Disease Found 2Health News:Genetic Links to Rare Liver Disease Found 3Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 2Health News:Longer Hormone Treatment May Improve Prostate Cancer Outlook 3Health News:FDA Panel OKs Newer Antipsychotics for Children 2Health News:FDA Panel OKs Newer Antipsychotics for Children 3Health News:FDA Panel OKs Newer Antipsychotics for Children 4Health News:Imaging Is Now Easier for the Area's Vulnerable Children 2Health News:Imaging Is Now Easier for the Area's Vulnerable Children 3Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 2Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 3Health News:ThermoGenesis Appoints Chief Executive Officer J. Melville ('Mel') Engle to Board of Directors 4Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 2Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 3Health News:TFAH Applauds 'Affordable Health Choices Act' for Making Prevention a Cornerstone of Health Reform 4
...
... laboratories looking for time and cost savings ... in terms of easy reagent cassette and ... stability., ,URISYS 2400 is a fully ... for medium to high volume laboratories with ...
Acufex arthroscopic electrodes are insulated for use in all fluids and come in boxes of 10....
... Spider Limited Wrist Fusion System ... 8-hole Spider plate and a ... have a unique three-dimensional design ... limited wrist arthrodeses, and both ...
Medicine Products: